Agomelatine

Drug Profile

Agomelatine

Alternative Names: AGO-178; AGO178C; Alodil; Melitor; S-20098; S-20098-F55; Thymanax; Valdoxan; Vestin

Latest Information Update: 14 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Servier
  • Developer Novartis; Servier
  • Class Acetamides; Antidepressants; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Suspended Generalised anxiety disorder
  • No development reported Obsessive-compulsive disorders
  • Discontinued Sleep disorders

Most Recent Events

  • 11 Aug 2017 Suspended - Phase-II for Generalised anxiety disorder (In adolescents, In children) in Poland, Romania, Estonia, Hungary, Sweden, Finland (PO,Tablet) (Servier email communication, August 2017)
  • 11 Aug 2017 Suspended - Phase-III for Generalised anxiety disorder in Canada, Poland, Russia, Czech Republic, Australia, Germany, Hungary, Slovakia, France, Ukraine, Finland, Argentina (PO,Capsule) (Servier email communication, August 2017)
  • 11 Aug 2017 Suspended - Phase-III for Generalised anxiety disorder in Slovakia, Russia, Poland, Czech Republic, France, Denmark, Sweden, Estonia, South Korea, Finland, Argentina (PO,Tablet) (Servier email communication, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top